Valuation
- Market cap
- 4,122,515,000
- Revenue TTM
- $62,380,000
- Net income TTM
- $-101,590,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -162.86%
- Debt to equity
- 0.00
Trading
- Volume
- 5,253,900
- Avg volume
- 2,658,430
- Day's range
- $23.09 – $25.09
- Shares out
- 168,610,000
- Stochastic %K
- 27%
- Beta
- 1.17
- Analysts
- Strong Sell
- Price target
- $43.50
Company profile
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for t...
Show more
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 320 4900
- Website
- https://www.tangotx.com
- Address
- 201 Brookline Avenue, Suite 901, Boston, United States
Latest news
No headlines yet.
